Price
$237.47+9.94%Social Signal Score
Analyst Ratings
14 analystsRevenue
$1.49B+130.92%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel A. Carestio
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Employees
- 17,937
- Beta
- 0.91
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 4.92
Financials
Revenue
$1.49B+130.9%Net Income
$200.10M+395.1%EBITDA
$349.40M+191.4%Free Cash Flow
$279.60M+301.3%EPS (diluted)
$2.04+334.0%Shares Outstanding (diluted)
97.90M+13.4%Operating Expenses
$28.60MCash & Debt
$482.30MReturn of Capital
$176.90MRevenue by Segment (annual)
$5.94BDividend per Share
$0.69Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $5.94B | $785.10M | $7.93 |
| 2025 | $5.46B | $614.64M | $6.24 |
| 2024 | $5.14B | $378.24M | $3.83 |
| 2023 | $4.54B | $107.03M | $1.07 |
| 2022 | $4.22B | $243.89M | $2.50 |
| 2021 | $3.11B | $397.40M | $4.66 |
| 2020 | $3.03B | $407.66M | $4.81 |
| 2019 | $2.78B | $304.05M | $3.59 |
| 2018 | $2.62B | $290.92M | $3.42 |
| 2017 | $2.61B | $109.97M | $1.29 |
| 2016 | $2.24B | $110.76M | $1.57 |
| 2015 | $1.85B | $135.06M | $2.27 |
| 2014 | $1.62B | $129.44M | $2.20 |
| 2013 | $1.50B | $159.98M | $2.74 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from STE's reported EPS growth of 8.5% a year over 13 years.
- EPS in 5 years
- $12.02
- Implied price
- $336.60
- Return from $208.54
- 10.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $167.35 — -19.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 20 | 24 | 28 | 32 | 36 |
|---|---|---|---|---|---|
| -1.5% | -6.6% | -3.1% | -0.1% | 2.6% | 5.1% |
| 3.5% | -1.9% | 1.8% | 5.0% | 7.8% | 10.4% |
| 8.5% | 2.9% | 6.7% | 10.0% | 13.0% | 15.7% |
| 13.5% | 7.6% | 11.6% | 15.1% | 18.2% | 21.1% |
| 18.5% | 12.4% | 16.5% | 20.2% | 23.4% | 26.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (5)
- Newsseekingalpha.com·20d ago·Positive
STERIS plc (STE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript STERIS plc (STE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
STERIS to Present at the Morgan Stanley Healthcare Conference Dublin, Ireland, Sept. 01, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will participate in the Morgan Stanley Healthcare Conference in New York City on Tuesday, September 15, 2026.
View source ↗ - Newszacks.com·45d ago·Neutral
Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales? STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.
View source ↗ - Newszacks.com·46d ago·Positive
Should Investors Buy STERIS as Growth Meets Reasonable Valuation? STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.
View source ↗ - Newsmarketbeat.com·58d ago·Neutral
STERIS Q1 Earnings Call Highlights STERIS NYSE: STE reported first-quarter fiscal 2027 revenue growth and higher earnings, while maintaining its full-year outlook and outlining a $600 million investment in a new chemistry manufacturing, research and distribution complex in North Carolina.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $2.67 per share
Typical surprise +3.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$2.59 vs $2.49beat
- Mon, May 11$2.83 vs $2.85miss
- Wed, Feb 4$2.53 vs $2.53beat
- Wed, Nov 5$2.47 vs $2.35beat
- Wed, Aug 6$2.34 vs $2.26beat
- Wed, May 14$2.74 vs $2.60beat
Estimates and results for STE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by STE officers and directors.
- Bought
- —
- Sold
- $9.1m
0 trades
12 trades
- Sohi Mohsensold
- Zangerle John Adamsold
- Carestio Daniel Asold
- Carestio Daniel Asold
- Breeden Richard Csold
- Feldmann Cynthia Lsold
- Madsen Juliasold
- Tamaro Renatosold
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (13d later)Sell$15,001 - $50,000
- April Delaneyhouse · MD06 · disclosed Sep 10, 2026 (16d later)Sell$100,001 - $250,000
- Jared Moskowitzhouse · FL23 · disclosed Aug 28, 2026 (46d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Aug 4, 2026 (4d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Aug 4, 2026 (11d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Aug 4, 2026 (8d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Aug 4, 2026 (6d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 9, 2026 (29d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 9, 2026 (27d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed May 11, 2026 (10d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed May 11, 2026 (12d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed May 7, 2026 (7d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Apr 8, 2026 (23d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Mar 11, 2026 (33d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Mar 10, 2026 (28d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Oct 7, 2025 (19d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Oct 7, 2025 (26d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Jul 3, 2025 (7d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 11, 2024 (28d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.